Blocking IL-1 and TNF

Fong Y. , Tracey KJ , Moldawer LL , Hesse DG , Manogue KB , Kenney JS et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627—1633.

Wakabayashi G. , Gelfand JA , Burke JF , Thompson RC , Dinarello CA A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock. FASEB J 1991; 5: 338—343.

Wolff SM Biological effects of bacterial endotoxins in man. J Infect Dis 1973; 128 (Suppl): 733—758.

Wallach D. , Holtmann H. , Engelmann H. , Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 1988; 140: 2994—2999.

Dinarello CA Biological basis for interleukin-1 in disease . Blood 1996; 87: 20952147.

Elliott MJ , Maini RN , Feldmann M. , Kalden JR , Antoni C. , Smolen JS et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis . Lancet 1994; 344: 1105—1110.

Lebsack ME , Paul CC , Martindale JJ , Catalano MA A dose- and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1993; 36: S39.

Bresnihan B. , Lookabaugh J. , Witt K. , Musikic P. Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized, double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996; 39: S73.

Watt I. , Cobby M. Recombinant human interleukin-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39: S123.

van Dullemen HM , van Deventer Sjh , Hommes DW , Bijl HA , Jansen J. , Tytgat GN et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129—135.

Antin JH , Weinstein HJ , Guinan EC , McCarthy P. , Bierer BE , Gilliland DG et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342—1348

Zeni F. , Freeman B. , Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment . Crit Care Med 1997; 25: 1095—1100.